AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
5,652.00
-18.00 (-0.32%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close5,670.00
Open5,670.00
Bid5,500.00 x 6100
Ask5,700.00 x 13000
Day's Range5,633.00 - 5,697.00
52 Week Range4,544.50 - 6,122.00
Volume912,842
Avg. Volume2,178,220
Market Cap71.598B
Beta1.27
PE Ratio (TTM)26.79
EPS (TTM)211.00
Earnings DateNov 8, 2018
Forward Dividend & Yield2.02 (3.58%)
Ex-Dividend Date2018-08-09
1y Target Est77.57
  • Reuters2 hours ago

    EU approves AstraZeneca immunotherapy drug for lung cancer

    AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker ...

  • AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
    Zacks3 hours ago

    AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk

    AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.

  • Reuters7 hours ago

    FOCUS-As China builds biotech sector, cash floods U.S. startups

    SAN FRANCISCO/HONG KONG, Sept 24 (Reuters) - For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company. Crammed in tight, four-person booths executives use for private conversations, the former GlaxoSmithKline PLC executive pitched dozens of U.S. biotech companies to partner with his start-up, Brii Biosciences. Months earlier, Hong had raised $260 million - much of it from Chinese and Asian investors - with a strategy to bring U.S. biotechnology drugs to China, the world’s second-largest prescription drug market and home to a rapidly growing biotech sector.

  • Reuters7 hours ago

    FOCUS-As China builds biotech sector, cash floods U.S. startups

    SAN FRANCISCO/HONG KONG, Sept 24 (Reuters) - For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company. Crammed in tight, four-person booths executives use for private conversations, the former GlaxoSmithKline PLC executive pitched dozens of U.S. biotech companies to partner with his start-up, Brii Biosciences. Months earlier, Hong had raised $260 million - much of it from Chinese and Asian investors - with a strategy to bring U.S. biotechnology drugs to China, the world’s second-largest prescription drug market and home to a rapidly growing biotech sector.

  • Reuters7 hours ago

    AstraZeneca diabetes drug cuts heart risks in major study

    AstraZeneca's diabetes drug Farxiga met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients, potentially distinguishing it from rivals in a crowded marketplace. Diabetics are at increased risk of heart problems, making the cardiovascular (CV) profile of medicines to treat the condition an important focus for doctors and patients.

  • Reutersyesterday

    AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • Reuters2 days ago

    AstraZeneca ceo warns of medicine shortages after Brexit - Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • 3 High-Yield Stocks at Rock-Bottom Prices
    Motley Fool2 days ago

    3 High-Yield Stocks at Rock-Bottom Prices

    Looking for big yield at a discount? These three could fit the bill.

  • NVS vs. AZN: Which Stock Is the Better Value Option?
    Zacks3 days ago

    NVS vs. AZN: Which Stock Is the Better Value Option?

    NVS vs. AZN: Which Stock Is the Better Value Option?

  • A Look at Shire’s Valuation on September 19
    Market Realist4 days ago

    A Look at Shire’s Valuation on September 19

    Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.

  • Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
    Zacks4 days ago

    Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

    In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

  • Reuters5 days ago

    FOCUS-AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON, Sept 19 (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters. Surrounded by the latest gizmos at the World Internet of Things Exposition in Wuxi, eastern China, Soriot says he wants to use the power of artificial intelligence, robots and apps to help transform diagnosis and disease management.

  • AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
    Zacks5 days ago

    AstraZeneca's Fasenra Long-Term Asthma Study Data Positive

    AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.

  • Reuters5 days ago

    Focus: AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.

  • AstraZeneca plots China robot offensive to counter price cuts
    Reuters5 days ago

    AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca (AZN.L) aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba (BABA.N) and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.

  • Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
    Zacks6 days ago

    Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

    Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

  • AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale
    Bloomberg7 days ago

    AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale

    ADC Therapeutics SA, a Swiss biotechnology company whose backers include U.K. drugmaker AstraZeneca Plc, is in the early stages of exploring options including an initial public offering amid growing interest in innovative cancer treatments, according to people familiar with the matter. ADC is working with advisers at Morgan Stanley on a preliminary review, the people said, asking not to be identified because the deliberations are private. The Lausanne-based company -- which specializes in treatments that target cancer cells while sparing healthy ones -- is also considering a potential sale among the options, they said.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks10 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
    Zacks10 days ago

    AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

    AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.

  • Johnson & Johnson Expands Blood Cancer Portfolio with Approval
    Market Realist10 days ago

    Johnson & Johnson Expands Blood Cancer Portfolio with Approval

    On August 27, Johnson & Johnson (JNJ) announced that it received FDA approval for its combination therapy of Imbruvica and Roche’s (RHHBY) rituximab for the treatment of WM (Waldenström’s macroglobulinemia), a rare blood cancer. According to JNJ, ~2,800 new WM cases are reported each year in the United States.

  • Reuters11 days ago

    FDA approves AstraZeneca's drug for rare form of blood cancer

    The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc's treatment for hairy cell leukemia, a slow-growing type of blood cancer. The treatment, marketed as Lumoxiti, was approved for treating a stubborn form of the disease or a relapse in patients who have received at least two prior therapies, the FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620448.htm said. Lumoxiti includes a boxed warning advising health care professionals and patients about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels.

  • Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
    Zacks11 days ago

    Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

    Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.

  • Motley Fool11 days ago

    3 Lung Cancer Stocks That Could End September on a High Note

    This year's World Conference on Lung Cancer has some important presentations scheduled.

  • Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
    Zacks12 days ago

    Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus

    Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.

  • The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson